Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress View Full Press Release Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS Travere Therapeutics Launches “Play It Forward” Campaign to Celebrate the FSGS Community on Inaugural Awareness Day